<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01773863</url>
  </required_header>
  <id_info>
    <org_study_id>MACCE and CAP</org_study_id>
    <nct_id>NCT01773863</nct_id>
  </id_info>
  <brief_title>MACCE in Hospitalized Patients With Community-acquired Pneumonia</brief_title>
  <official_title>Major Adverse Cardiac and Cerebrovascular Events in Hospitalized Patients With Community-acquired Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Community-acquired pneumonia is the most common infection leading to hospitalization in&#xD;
      intensive care units and the most common cause of death associated with infection disease.&#xD;
&#xD;
      Epidemiological studies have shown that respiratory tract infections are associated with an&#xD;
      increased risk for the development of acute cardiovascular and cerebrovascular events.&#xD;
&#xD;
      This link is further supported by studies indicating that influenza vaccination is associated&#xD;
      with a reduced risk of hospitalization for pneumonia as well as heart disease and&#xD;
      cerebrovascular disease.&#xD;
&#xD;
      Data connecting acute respiratory tract infections and cardiovascular events stem almost&#xD;
      exclusively from cross-sectional or retrospective studies. Thus the real incidence and the&#xD;
      prognostic impact of AMI, as well as the pathophysiological relationship between pneumonia&#xD;
      and cardiovascular damage is still elusive.&#xD;
&#xD;
      Inflammation plays a major role in the pathogenesis of coronary artery disease. The increased&#xD;
      concentrations of proinflammatory cytokines together with the activation of coagulation, the&#xD;
      down-regulation of anticoagulant mechanisms and the enhanced platelet aggregation may trigger&#xD;
      atheroma's instability, plaque rupture and thrombus formation.&#xD;
&#xD;
      Inflammation and coagulopathy are also considered universal host responses to infection in&#xD;
      patients with severe sepsis. Thus far limited data are available on the changes in these high&#xD;
      regulated systems, together with platelet activity in patients with CAP and their potential&#xD;
      relationship with cardiovascular risk.&#xD;
&#xD;
      This project will consist in a prospective multicenter study to investigate the incidence of&#xD;
      major adverse cardiac and cerebrovascular events (MACCE) in hospitalized patients with CAP,&#xD;
      its prognostic relevance and the potential relationship between enhanced cardiovascular risk&#xD;
      and the activation of inflammation, coagulation and platelet aggregation in this setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Community-acquired pneumonia (CAP) is the most common infection leading to hospitalization in&#xD;
      intensive care units and the most common cause of death associated with infection disease.&#xD;
&#xD;
      Epidemiological studies have shown that respiratory tract infections are associated with an&#xD;
      increased risk for the development of acute cardiovascular and cerebrovascular events.&#xD;
&#xD;
      This link is further supported by studies indicating that influenza vaccination is associated&#xD;
      with a reduced risk of hospitalization for pneumonia as well as heart disease,&#xD;
      cerebrovascular disease and the risk of death from all causes during influenza seasons in&#xD;
      elderly.&#xD;
&#xD;
      Data connecting acute respiratory tract infections and cardiovascular events stemmed almost&#xD;
      exclusively from cross-sectional or retrospective studies and the pathophysiological&#xD;
      relationship between pneumonia and cardiovascular damage is still elusive.&#xD;
&#xD;
      The first aim of the study will be to analyze the prevalence of major adverse cardiac and&#xD;
      cerebrovascular events (MACCE) in patients hospitalized for CAP, followed up for two years&#xD;
      after hospitalization.&#xD;
&#xD;
      During hospitalization myocardial damage will be strictly monitored by measuring cardiac&#xD;
      troponins until discharge.&#xD;
&#xD;
      Cardiac troponins are established markers of myocardial damage. Cardiac troponin elevation is&#xD;
      seen not only in the setting of acute coronary syndromes but also in a variety of conditions&#xD;
      not directly related to flow-limiting coronary stenosis or occlusion of the coronary&#xD;
      arteries, such as pulmonary embolism, sepsis, heart failure and stroke. In these settings, it&#xD;
      is well documented that elevated circulating levels of troponins are associated with poor&#xD;
      prognosis, regardless of underlying disease.&#xD;
&#xD;
      Sparse information exists concerning the significance of troponin elevation during&#xD;
      respiratory tract infections. Most of the studies investigated the role of troponin elevation&#xD;
      in patients admitted in hospital for acutely exacerbated chronic obstructive pulmonary&#xD;
      disease (COPD); only a recent study investigates specifically CAP, showing a correlation&#xD;
      between troponin elevation and oxygenation impairment; however, the underlying mechanism was&#xD;
      not explored.&#xD;
&#xD;
      Inflammation plays a major role in the pathogenesis of coronary artery disease. The increased&#xD;
      concentrations of proinflammatory cytokines together with the activation of coagulation, the&#xD;
      down-regulation of anticoagulant mechanisms and the enhanced platelet aggregation may trigger&#xD;
      atheroma's instability, plaque rupture and thrombus formation.&#xD;
&#xD;
      Systemic coagulation abnormalities including clotting activation and inhibition of&#xD;
      anticoagulant factors have been observed in patients with severe sepsis; in patients with CAP&#xD;
      similar changes have been detected only in the lung compartment. Changes of clotting system&#xD;
      activation are of potential relevance as they could elicit myocardial damage with several&#xD;
      mechanisms including coronary ischemia and/or direct inflammation of cardiac cells.&#xD;
      Concerning this last point it is of interest that Protein C, an anticoagulant factor with&#xD;
      anti-inflammatory property, is reduced in severe sepsis where it correlates with disease&#xD;
      severity and mortality. Accordingly, infusion of recombinant human activated Protein C&#xD;
      improves survival of patients with severe sepsis due to pneumococcal pneumonia.&#xD;
&#xD;
      Until now no data exists about the behavior of Protein C in patients with CAP and its&#xD;
      interplay with myocardial damage.&#xD;
&#xD;
      Moreover no data on platelet reactivity and activation during pneumonia exist. Very limited&#xD;
      data is only available on common viral respiratory tract infections in which enhanced&#xD;
      platelet reactivity has been shown.&#xD;
&#xD;
      The investigators speculated that inhibition of Protein C as well as enhanced platelet&#xD;
      activity may be implicated in myocardial damage in patients with CAP. Therefore the&#xD;
      investigators will perform a prospective study to investigate whether this relationship&#xD;
      exist.&#xD;
&#xD;
      Data obtained could have important clinical consequences: new therapeutic strategies&#xD;
      targeting these systems could prevent myocardial damage and eventually MACCEs in these&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2011</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Actual">April 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet activation, clotting abnormalities, myocardial damage and inflammation in CAP patients</measure>
    <time_frame>2 years</time_frame>
    <description>Platelet and serum thromboxane, F2-isoprostanes, NOX2-activation, serum high-sensitivity cardiac troponin T, protein C and protein S at hospital admission and at hospital discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac and cerebrovascular events</measure>
    <time_frame>2 years</time_frame>
    <description>Major adverse cardiac and cerebrovascular events will be assessed during hospitalization and during the follow-up</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Community-acquired Pneumonia</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, serum and urine samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients hospitalized for community-acquired pneumonia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  community-acquired pneumonia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  presence of immunosuppression (HIV infection, high dose of immunosuppressive agents&#xD;
             such as prednisone, chemotherapy);&#xD;
&#xD;
          -  presence of malignancy;&#xD;
&#xD;
          -  pregnancy or breast feeding;&#xD;
&#xD;
          -  health care-associated pneumonia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Violi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sapienza University of Rome</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Cangemi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sapienza University of Rome</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Cangemi</last_name>
    <role>Study Director</role>
    <affiliation>Sapienza - Unviersity of Rome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Violi, MD</last_name>
    <phone>064461933</phone>
    <phone_ext>+39</phone_ext>
    <email>francesco.violi@uniroma1.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roberto Cangemi, MD</last_name>
    <phone>0649970103</phone>
    <phone_ext>+39</phone_ext>
    <email>roberto.cangemi@uniroma1.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Internal and Medical Specialities Department - Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <zip>00162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Violi, MD</last_name>
      <phone>064461933</phone>
      <phone_ext>+39</phone_ext>
      <email>francesco.violi@uniroma1.it</email>
    </contact>
    <contact_backup>
      <last_name>Roberto Cangemi, MD</last_name>
      <phone>0649970103</phone>
      <email>roberto.cangemi@uniroma1.it</email>
    </contact_backup>
    <investigator>
      <last_name>Francesco Violi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cangemi Roberto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Cangemi R, Calvieri C, Bucci T, Carnevale R, Casciaro M, Rossi E, Calabrese CM, Taliani G, Grieco S, Falcone M, Palange P, Bertazzoni G, Celestini A, Pignatelli P, Violi F; SIXTUS study group. Is NOX2 upregulation implicated in myocardial injury in patients with pneumonia? Antioxid Redox Signal. 2014 Jun 20;20(18):2949-54. doi: 10.1089/ars.2013.5766. Epub 2014 Mar 14.</citation>
    <PMID>24328853</PMID>
  </results_reference>
  <results_reference>
    <citation>Cangemi R, Casciaro M, Rossi E, Calvieri C, Bucci T, Calabrese CM, Taliani G, Falcone M, Palange P, Bertazzoni G, Farcomeni A, Grieco S, Pignatelli P, Violi F; SIXTUS Study Group; SIXTUS Study Group. Platelet activation is associated with myocardial infarction in patients with pneumonia. J Am Coll Cardiol. 2014 Nov 4;64(18):1917-25. doi: 10.1016/j.jacc.2014.07.985. Epub 2014 Oct 27.</citation>
    <PMID>25444147</PMID>
  </results_reference>
  <results_reference>
    <citation>Cangemi R, Calvieri C, Falcone M, Bucci T, Bertazzoni G, Scarpellini MG, Barill√† F, Taliani G, Violi F; SIXTUS Study Group. Relation of Cardiac Complications in the Early Phase of Community-Acquired Pneumonia to Long-Term Mortality and Cardiovascular Events. Am J Cardiol. 2015 Aug 15;116(4):647-51. doi: 10.1016/j.amjcard.2015.05.028. Epub 2015 May 22.</citation>
    <PMID>26089009</PMID>
  </results_reference>
  <results_reference>
    <citation>Violi F, Carnevale R, Calvieri C, Nocella C, Falcone M, Farcomeni A, Taliani G, Cangemi R; SIXTUS study group. Nox2 up-regulation is associated with an enhanced risk of atrial fibrillation in patients with pneumonia. Thorax. 2015 Oct;70(10):961-6. doi: 10.1136/thoraxjnl-2015-207178. Epub 2015 Jun 29.</citation>
    <PMID>26123660</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 18, 2013</study_first_submitted>
  <study_first_submitted_qc>January 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2013</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Francesco Violi</investigator_full_name>
    <investigator_title>Director, Head of Internal Medicine, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Community-acquired pneumonia</keyword>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Platelet activation</keyword>
  <keyword>Coagulation abnormalities,</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>Isoprosantes</keyword>
  <keyword>NADPH oxidase</keyword>
  <keyword>Major adverse cardiac and cerebrovascular events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

